Get the Stockscreener App
5.59
0.18%
0.010
After Hours:
5.63
0.04
+0.72%
Trisalus Life Sciences Inc stock is traded at $5.59, with a volume of 38,815.
It is up +0.18% in the last 24 hours and up +8.33% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$5.58
Open:
$5.61
24h Volume:
38,815
Relative Volume:
0.96
Market Cap:
$170.46M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-3.1903
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
+4.49%
1M Performance:
+8.33%
6M Performance:
-1.24%
1Y Performance:
-42.49%
1-Day Range:
$5.48
$5.66
1-Week Range:
$5.11
$5.67
52-Week Range:
$3.50
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.59 | 170.46M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
131.44 | 227.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.98 | 156.20B | 16.75B | 1.85B | 1.89B | 1.25 |
|
SYK
Stryker Corp
|
390.48 | 148.86B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.20 | 116.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.82B | 6.60B | 4.16B | 490.10M | 6.93 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock - MarketBeat
Financial Comparison: TriSalus Life Sciences (NASDAQ:TLSI) versus Tenon Medical (NASDAQ:TNON) - Defense World
Tenon Medical (NASDAQ:TNON) vs. TriSalus Life Sciences (NASDAQ:TLSI) Head to Head Survey - Armenian Reporter
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young Purchases 6,000 Shares - Armenian Reporter
CFO Makes Bold Move with Major Stock Purchase in TriSalus Life Sciences! - TipRanks
Trisalus Life Sciences CFO buys $33,900 in common stock By Investing.com - Investing.com Canada
Trisalus Life Sciences CFO buys $33,900 in common stock - Investing.com
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $11.79 - Defense World
TriSalus Life Sciences bolsters board with two new members - MSN
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Purchases $25,300.90 in Stock - MarketBeat
TriSalus Life Sciences announces drawdown of $10M under credit agreement with OrbiMed - MSN
Trisalus Life Sciences Announces Key Appointments To Board Of Directors -February 03, 2025 at 05:03 pm EST - Marketscreener.com
TriSalus Life Sciences bolsters board with two new members By Investing.com - Investing.com South Africa
Healthcare Powerhouses Join TriSalus Board: Ex-Fresenius CEO and AbbVie Oncology Pioneer Unite - StockTitan
TriSalus Life Sciences, Inc. Announces Drawdown of $10 Million Tranche Under Credit Agreement with Orbimed - Marketscreener.com
Revenue Success: TriSalus Unlocks $10M Strategic Funding from Healthcare Giant OrbiMed - StockTitan
Trisalus life sciences director Sean Murphy buys $157,200 in stock - MSN
TriSalus Life Sciences expands board, appoints new directors By Investing.com - Investing.com Nigeria
TriSalus Life Sciences expands board, appoints new directors - MSN
Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases 24,000 Shares of Stock - MarketBeat
Mary T. Szela Purchases 4,826 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock - MarketBeat
Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Purchases 15,000 Shares of Stock - MarketBeat
Trisalus life sciences CFO buys shares worth $129,600 - MSN
Trisalus life sciences CEO buys $50,302 in stock - MSN
Trisalus life sciences CEO buys $50,302 in stock By Investing.com - Investing.com Australia
TriSalus Life Sciences (NASDAQ:TLSIW) Trading Down 2.9% – What’s Next? - Defense World
Trisalus life sciences CFO buys shares worth $129,600 By Investing.com - Investing.com Australia
Mary Szela Increases Stake in TriSalus Life Sciences Inc (TLSI) with Recent Share Purchase - GuruFocus.com
Trisalus life sciences director Sean Murphy buys $157,200 in stock By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Earns “Buy” Rating from Roth Mkm - Defense World
TriSalus reports 59% annual revenue growth in 2024 By Investing.com - Investing.com Australia
TriSalus Life Sciences (NASDAQ:TLSI) Given "Buy" Rating at Roth Mkm - MarketBeat
TriSalus reports 59% annual revenue growth in 2024 - MSN
TriSalus Life Sciences Reports 59% Revenue Surge to $29.4M, Projects Strong 2025 Growth - StockTitan
TriSalus Life Sciences names new finance chief - MSN
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):